Acute Biphenotypic Leukemia (ABL) Recruiting Phase 2 Trials for Fludarabine (DB01073)

Also known as: Acute biphenotypic leukaemia / Acute Biphenotypic Leukemia / Leukemia, Biphenotypic, Acute / Acute bilineal leukemia

IndicationStatusPhase
DBCOND0081399 (Acute Biphenotypic Leukemia (ABL))Recruiting2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT02220985Selective Depletion of CD45RA+ T Cells From Allogeneic Peripheral Blood Stem Cell Grafts From HLA-Matched Related and Unrelated Donors in Preventing GVHDTreatment
NCT03970096Graft Versus Host Disease-Reduction Strategies for Donor Blood Stem Cell Transplant Patients With Acute LeukemiaTreatment
NCT02727803Personalized NK Cell Therapy After Chemotherapy and Cord Blood Transplant in Treating Patients With Myelodysplastic Syndrome, Leukemia, Lymphoma or Multiple MyelomaTreatment
NCT03779854Naive T Cell Depletion for Preventing Chronic Graft-versus-Host Disease in Children and Young Adults With Blood Cancers Undergoing Donor Stem Cell TransplantTreatment
NCT01028716Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic MalignanciesTreatment
NCT00719888Umbilical Cord Blood Transplant, Cyclophosphamide, Fludarabine, and Total-Body Irradiation in Treating Patients With Hematologic DiseaseTreatment